A Case Report on Prolonged Response With Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting. J. Can. Res. Updates 2023, 12, 49-53. https://doi.org/10.30683/1929-2279.2023.12.9.